The Suppression of Ovarian Function Trial (SOFT) and the Tamoxifen and Exemestane Trial (TEXT) enrolled premenopausal women with hormone receptor-positive early breast cancer [45, 46]. This evidence concerns the gene NR4A1 and breast carcinoma.